Top ▲
Target id: 2954
Nomenclature: Plasmodium falciparum phenylalanyl-tRNA synthetase alpha subunit
Abbreviated Name: PfcFRS
Family: Aminoacyl-tRNA synthetases
Gene and Protein Information | ||||||
Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
Plasmodium falciparum 3D7 | - | 575 | cPheRS | phenylalanine--tRNA ligase alpha subunit | ||
Gene and Protein Information Comments | ||||||
The phenylalanyl-tRNA synthetases (FRSs) are unique within the aaRS family because the P. falciparum genome contains four genes that encode three distinct FRSs: cytosolic (heterodimeric cFRS; the α-subunit, described here; β-subunit, PF3D7_1104000), apicoplast (PF3D7_1232000), and mitochondrial FRS (PF3D7_0603700) [1,4]. |
Previous and Unofficial Names |
Pf3D7_01_v3:380,254..382,568(+) | PfcPheRS | PFA0480w | Plasmodium falciparum phenylalanine--tRNA ligase alpha subunit |
Database Links | |
Alphafold | Q8I246 (Pf3D7) |
PlasmoDB | PF3D7_0109800 (Pf3D7) |
UniProtKB | Q8I246 (Pf3D7) |
Download all structure-activity data for this target as a CSV file
Inhibitors | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | View all chemical structures | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Whole Organism Assay Data Linked to This Target | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Malaria Pharmacology Comments |
The three PfFRSs are class II aaRSs [1]. The aaRSs are emerging targets for antimalarial agents (reviewed in [4]), with PfcFRS the first member of the family whose inhibition results in elimination of asexual blood, liver and transmission-stage parasites [3]. PfcFRS is ranked as a "High Priority" target in the Malaria Drug Accelerator (MalDA) portfolio [2]. |
1. Bhatt TK, Kapil C, Khan S, Jairajpuri MA, Sharma V, Santoni D, Silvestrini F, Pizzi E, Sharma A. (2009) A genomic glimpse of aminoacyl-tRNA synthetases in malaria parasite Plasmodium falciparum. BMC Genomics, 10: 644. [PMID:20042123]
2. Forte B, Ottilie S, Plater A, Campo B, Dechering KJ, Gamo FJ, Goldberg DE, Istvan ES, Lee M, Lukens AK et al.. (2021) Prioritization of Molecular Targets for Antimalarial Drug Discovery. ACS Infect Dis, 7 (10): 2764-2776. [PMID:34523908]
3. Kato N, Comer E, Sakata-Kato T, Sharma A, Sharma M, Maetani M, Bastien J, Brancucci NM, Bittker JA, Corey V et al.. (2016) Diversity-oriented synthesis yields novel multistage antimalarial inhibitors. Nature, 538 (7625): 344-349. [PMID:27602946]
4. Manickam Y, Chaturvedi R, Babbar P, Malhotra N, Jain V, Sharma A. (2018) Drug targeting of one or more aminoacyl-tRNA synthetase in the malaria parasite Plasmodium falciparum. Drug Discov Today, 23 (6): 1233-1240. [PMID:29408369]
Aminoacyl-tRNA synthetases: Plasmodium falciparum phenylalanyl-tRNA synthetase alpha subunit. Last modified on 29/03/2022. Accessed on 06/12/2024. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetomalariapharmacology.org/GRAC/ObjectDisplayForward?objectId=2954.